Cognitive Development in Infantile-Onset Pompe Disease Under Very Early Enzyme Replacement Therapy

Abstract

Most patients with infantile-onset Pompe disease die in early infancy before beginning enzyme replacement therapy, which has made it difficult to evaluate the impact of Pompe disease on cognitive development. Patients with infantile-onset Pompe disease can survive with enzyme replacement therapy, and physicians can evaluate cognitive development in these patients. We established an effective newborn screening program with quick clinical diagnostic criteria. Cognitive and motor development were evaluated using the Bayley Scales of Infant and Toddler Development–Third Edition at 6, 12, and 24 months of age. The patients who were treated very early demonstrate normal cognitive development with no significant change in cognition during this period (P = .18 > .05). The cognitive development was positively correlated with motor development (r = 0.533, P = .011). The results indicated that very early enzyme replacement therapy could protect cognitive development in patients with infantile-onset Pompe disease up to 24 months of age.

Keywords

infantile-onset Pompe disease cognitive development enzyme replacement therapy

Get full access to this article

View all access options for this article.

References

Cho

Kim

Lim

. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy. J Child Neurol. 2012;27:319–324.

Kishnani

Corzo

Nicolino

. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68:99–109.

Germain

. Enzyme replacement therapies for lysosomal storage disorders. Med Sci (Paris). 2005;21:77–83.

Prater

Banugaria

DeArmey

. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med. 2012;14:800–810.

Case

Beckemeyer

Kishnani

. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations. Am J Med Genet C Semin Med Genet. 2012;160C:69–79.

Yang

Liu

Hsu

. A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment. Am J Med Genet A. 2014;164A:54–61.

Chien

Chiang

Zhang

. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics. 2008;122:e39–e45.

Shotelersuk

Shuangshoti

Chotivitayatarakorn

. Clinical, pathological, and electron microscopic findings in two Thai children with Pompe disease. J Med Assoc Thai. 2002;85:S271–S279.

Martini

Ciana

Benettoni

. Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2. Neurology. 2001;57:906–908.

10.

Chen

Lin

Tzen

Tsai

Hwu

Wang

. Detection of a homozygous D645E mutation of the acid alpha-glucosidase gene and glycogen deposition in tissues in a second-trimester fetus with infantile glycogen storage disease type II. Prenat Diagn. 2004;24:231–232.

11.

Begley

Pontikis

Scarpa

. Lysosomal storage diseases and the blood-brain barrier. Curr Pharm Des. 2008;14:1566–1580.

12.

Pena

Proia

Kishnani

. Postmortem findings and clinical correlates in individuals with infantile-onset Pompe disease. JIMD Rep. 2015;23:45–54.

13.

Chien

Lee

Peng

Hwu

. Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy. Pediatr Res. 2006;60:349–352.

14.

Rohrbach

Klein

Kohli-Wiesner

. CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis. 2010;33:751–757.

15.

van den Hout

Hop

van Diggelen

. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112:332–340.

16.

Spiridigliozzi

Heller

Kishnani

. Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up. Am J Med Genet C Semin Med Genet. 2012;160C:22–29.

17.

Ebbink

Aarsen

van Gelder

. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Neurology. 2012;78:1512–1518.

18.

Spiridigliozzi

Heller

Case

Jones

Kishnani

. Early cognitive development in children with infantile Pompe disease. Mol Genet Metab. 2012;105:428–432.

19.

Albers

CAG

Adam

. Review of Bayley Scales of Infant and Toddler Development—Third Edition. J Psychoeduc Assess. 2007;25:180–190.

20.

Kishnani

Beckemeyer

Mendelsohn

. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. Am J Med Genet C Semin Med Genet. 2012;160C:1–7.

21.

Chaudhari

Bhalerao

Chitale

Pandit

Nene

. Pune low birth weight study—a six year follow up. Indian Pediatr. 1999;36:669–676.

22.

Kishnani

Hwu

Mandel

Nicolino

Yong

Corzo

; Infantile-Onset Pompe Disease Natural History Study Group. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr. 2006;148:671–676.